2005 Sep 28;294(12):1491]
If youve tried either one, what did you notice
This represents a 6075% cost reduction, but compounded tirzepatide is not covered by insurance and must be paid out-of-pocket
When patients refill their multi-dose pen prescription on the LillyDirect digital health platform, they will pay no more than $449
Important factors affecting GLP-1 market demand and take-up include: The need for better long-term data on the safety and efficacy of use for the designated indications The rapidly expanding list of potential new indications for the drugs, including chronic kidney disease, broader cardiovascular risk reduction, metabolic liver disease, and Alzheimer's disease The number of similar drugs in the development pipeline Price point versus competition, which affects affordability and insurance coverage Marketing efforts of the manufacturers, supply and distribution constraints
In Alzheimers disease, the production of pro-inflammatory factors and A can over-activate microglia, secrete inflammatory factors and neurotoxins, and then induce neuronal damage and even apoptosis, thereby triggering Alzheimers disease
